Loading
A Swiss trial asked whether lung cancer that has reached the lymph nodes in the middle of the chest does better with radiotherapy added to chemotherapy before the operation. It did not, which spared patients a treatment that adds side effects without adding benefit.
SAKK 16/00 enrolled 232 patients with pathologically proven stage IIIA/N2 non-small-cell lung cancer at 23 centres in Switzerland, Germany and Serbia between 2001 and 2012. Everyone received three cycles of cisplatin 100 mg/m2 and docetaxel 85 mg/m2; 117 were randomised to radiotherapy of 44 Gy in 22 fractions over three weeks before surgery and 115 to surgery after chemotherapy alone. Median event-free survival, the primary endpoint, was 12.8 months with radiotherapy and 11.6 months without (p=0.67); median overall survival was 37.1 and 26.2 months, with wide confidence intervals. Grade 3 dysphagia from radiotherapy occurred in 7 per cent. The authors concluded that one definitive local treatment combined with induction chemotherapy is adequate. It was funded by the Swiss State Secretariat for Education, Research and Innovation, the Swiss Cancer League and Sanofi.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
232 enrolled.
95 per cent CI 9.7 to 22.9 · 95 per cent CI 8.4 to 15.2
SourceShares Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial (SAKK 16/00), Non-small-cell lung cancer.
Shares Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial (SAKK 16/00), Swiss Cancer Institute (formerly SAKK), Non-small-cell lung cancer.
Shares Surgery and radiotherapy cure most, get least, Non-small-cell lung cancer.
Shares Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial (SAKK 16/00), Swiss Cancer Institute (formerly SAKK), Non-small-cell lung cancer.
Shares Surgery and radiotherapy cure most, get least, Non-small-cell lung cancer.
Shares Surgery and radiotherapy cure most, get least, Non-small-cell lung cancer.
Shares Swiss Cancer Institute (formerly SAKK), Non-small-cell lung cancer.
Shares Swiss Cancer Institute (formerly SAKK), Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/